| 1 | whom | 7,851 |
| 2 | qizhi | 7 |
| 3 | review- | 6 |
| 4 | anti-infective-treated | 5 |
| 5 | arba | 5 |
| 6 | bias.for | 5 |
| 7 | 5498 | 4 |
| 8 | analysis.there | 4 |
| 9 | canales | 4 |
| 10 | coprinus | 4 |
| 11 | gd-2 | 4 |
| 12 | glucose/sucrose | 4 |
| 13 | pcc+pce | 4 |
| 14 | sabal | 4 |
| 15 | vhr | 4 |
| 16 | enucleating | 3 |
| 17 | hepa-1 | 3 |
| 18 | legitimizing | 3 |
| 19 | npp/kg | 3 |
| 20 | ~1000 | 3 |
| 21 | 100-1000k | 2 |
| 22 | 1979-82 | 2 |
| 23 | 1985-1997 | 2 |
| 24 | 21,457 | 2 |
| 25 | 35,869 | 2 |
| 26 | 3873 | 2 |
| 27 | amir-al-momenin | 2 |
| 28 | articles.we | 2 |
| 29 | customising | 2 |
| 30 | cygb-mediated | 2 |
| 31 | dabrowa | 2 |
| 32 | domperidone/kg | 2 |
| 33 | evidence.whereas | 2 |
| 34 | flp-in | 2 |
| 35 | ft4-levels | 2 |
| 36 | gidan | 2 |
| 37 | hydroscopicity | 2 |
| 38 | icrf | 2 |
| 39 | ict-ccrt | 2 |
| 40 | jbir-108 | 2 |
| 41 | newborns/infants | 2 |
| 42 | parthenoclone | 2 |
| 43 | perdeuterated | 2 |
| 44 | postbunionectomy | 2 |
| 45 | pre-abortion | 2 |
| 46 | pre-maturely | 2 |
| 47 | previously-studied | 2 |
| 48 | top-dose | 2 |
| 49 | viewing- | 2 |
| 50 | wwox-related | 2 |
| 51 | yangchangwan | 2 |
| 52 | świetokrzyskie | 2 |
| 53 | €50 | 2 |
| 54 | 'jumping | 1 |
| 55 | 'marrying | 1 |
| 56 | 'redesigning | 1 |
| 57 | -20mpa | 1 |
| 58 | 0.018-0.032mg/kg | 1 |
| 59 | 0.1349 | 1 |
| 60 | 01.01-31.12.2001 | 1 |
| 61 | 1,090,640 | 1 |
| 62 | 1,4-diaryl-1,2,3-triazoles | 1 |
| 63 | 1,7-seco-2,7'-cyclolignane | 1 |
| 64 | 1-3+ | 1 |
| 65 | 1.3g/l/h | 1 |
| 66 | 1.8min | 1 |
| 67 | 10.6°/cm | 1 |
| 68 | 10/1980-12/1985 | 1 |
| 69 | 10cm² | 1 |
| 70 | 110,718 | 1 |
| 71 | 12,450 | 1 |
| 72 | 120-200mg/dl | 1 |
| 73 | 130-165°f | 1 |
| 74 | 14-membered-ring | 1 |
| 75 | 15-25°c | 1 |
| 76 | 15-30/h | 1 |
| 77 | 15mg/day | 1 |
| 78 | 18,510 | 1 |
| 79 | 18,571 | 1 |
| 80 | 1928-1953 | 1 |
| 81 | 1954-2003 | 1 |
| 82 | 1982-1985 | 1 |
| 83 | 1h-pyrrolizine | 1 |
| 84 | 2,3,4,9-tetrahydro-1h-carbazol-1-one | 1 |
| 85 | 2,5-diphenyl-1,3,4-oxadiazoles | 1 |
| 86 | 2-amino-2-deoxy-d-glucose | 1 |
| 87 | 2-amino-2-methyl-1,3-propanediol | 1 |
| 88 | 2.92° | 1 |
| 89 | 20,400 | 1 |
| 90 | 2003-surpassing | 1 |
| 91 | 20cigarettes/day | 1 |
| 92 | 222,148 | 1 |
| 93 | 23.4-27.5 | 1 |
| 94 | 2374/53 | 1 |
| 95 | 24,075 | 1 |
| 96 | 28,107 | 1 |
| 97 | 3,17-dicarboxamides | 1 |
| 98 | 3,3'-dimethoxy-7,7'-epoxylignane-4,4'-diol | 1 |
| 99 | 3,903 | 1 |
| 100 | 3-aryl-3-arylmethoxy-azetidines | 1 |
| 101 | 3-arylideneflavanones | 1 |
| 102 | 300. | 1 |
| 103 | 300±30μm | 1 |
| 104 | 36755 | 1 |
| 105 | 372bp | 1 |
| 106 | 3h-l-glucose | 1 |
| 107 | 4'-methylbiphenyl-2-carbonitrile | 1 |
| 108 | 4-aryl-3-methyl-4-piperidinemethanols | 1 |
| 109 | 4.1±1.4mm | 1 |
| 110 | 4.3±0.1 | 1 |
| 111 | 4/107 | 1 |
| 112 | 40-80mg/day | 1 |
| 113 | 40degrees | 1 |
| 114 | 4402 | 1 |
| 115 | 5,945 | 1 |
| 116 | 5-substituted-2-amino-1,3,4-thiadiazoles | 1 |
| 117 | 5-substituted-3,4-diphenylfuran-2-ones | 1 |
| 118 | 519/14 | 1 |
| 119 | 5504 | 1 |
| 120 | 59,800 | 1 |
| 121 | 6,586 | 1 |
| 122 | 6.1+/-5.6 | 1 |
| 123 | 6.4-4.5 | 1 |
| 124 | 61° | 1 |
| 125 | 6366 | 1 |
| 126 | 64,236 | 1 |
| 127 | 68,230 | 1 |
| 128 | 6m2c | 1 |
| 129 | 70±10years | 1 |
| 130 | 75045 | 1 |
| 131 | 8191 | 1 |
| 132 | 81of | 1 |
| 133 | 83.7years | 1 |
| 134 | 8862 | 1 |
| 135 | 90°on | 1 |
| 136 | 9114 | 1 |
| 137 | 9819 | 1 |
| 138 | 99mtc-diphosphonates | 1 |
| 139 | abuse/use | 1 |
| 140 | action-targeting | 1 |
| 141 | activation-timing | 1 |
| 142 | ad-though | 1 |
| 143 | ad.1,2 | 1 |
| 144 | adhd/hkd | 1 |
| 145 | adhesive-tape | 1 |
| 146 | adhesive/cement | 1 |
| 147 | adipositas++ | 1 |
| 148 | affixing | 1 |
| 149 | africa׳s | 1 |
| 150 | agropyron | 1 |
| 151 | aiden.what | 1 |
| 152 | ais/tia | 1 |
| 153 | alkalinising | 1 |
| 154 | all-cis-1,2,4,5- | 1 |
| 155 | allele*3 | 1 |
| 156 | alpha2m | 1 |
| 157 | aminomutases | 1 |
| 158 | anal-gesia | 1 |
| 159 | ancylostomids | 1 |
| 160 | android-based | 1 |
| 161 | anti-1,2-disubstituted-3,4-pentadien-1-amines | 1 |
| 162 | antimicrobics | 1 |
| 163 | antzg1 | 1 |
| 164 | any-duration | 1 |
| 165 | aortosclerosis | 1 |
| 166 | aroclors | 1 |
| 167 | asia-for | 1 |
| 168 | atorvastatin/simvastatin | 1 |
| 169 | awareness-before | 1 |
| 170 | bacteriophagetherapy | 1 |
| 171 | bal-cells | 1 |
| 172 | bayankhongor | 1 |
| 173 | beamlets | 1 |
| 174 | benzofuroindolines | 1 |
| 175 | betaine/l | 1 |
| 176 | bias'assessment | 1 |
| 177 | bias.amongst | 1 |
| 178 | bias.in | 1 |
| 179 | bias.only | 1 |
| 180 | bicuspidizing | 1 |
| 181 | biodoor | 1 |
| 182 | biosubstrates | 1 |
| 183 | blinding.in | 1 |
| 184 | bmp2+tgfβ1 | 1 |
| 185 | bp-3was | 1 |
| 186 | butaconazole | 1 |
| 187 | c1+2 | 1 |
| 188 | ca-725 | 1 |
| 189 | calf-raises | 1 |
| 190 | callovo-oxfordian | 1 |
| 191 | cams-how | 1 |
| 192 | cases.at | 1 |
| 193 | cbt/ex | 1 |
| 194 | cctvs | 1 |
| 195 | cdc-treatment | 1 |
| 196 | cddp-5fu | 1 |
| 197 | cddp.at | 1 |
| 198 | cementing.in | 1 |
| 199 | centreing | 1 |
| 200 | cgog | 1 |
| 201 | child-sizing | 1 |
| 202 | children.overall | 1 |
| 203 | chldren | 1 |
| 204 | choleretics | 1 |
| 205 | col4a3/β-actin | 1 |
| 206 | control.citalopram | 1 |
| 207 | controls-a | 1 |
| 208 | cross-trimester | 1 |
| 209 | crt-d/icd | 1 |
| 210 | ct3n0-1m0 | 1 |
| 211 | cyanide-bound | 1 |
| 212 | d/adc | 1 |
| 213 | dairycomp | 1 |
| 214 | diabetes-hypertension-hypercholesterolemia | 1 |
| 215 | dicontinuating | 1 |
| 216 | disadvantaging | 1 |
| 217 | discolouring | 1 |
| 218 | discontination | 1 |
| 219 | discontinuation/switching | 1 |
| 220 | discussion.in | 1 |
| 221 | diseases-version | 1 |
| 222 | dsm-iv-ad | 1 |
| 223 | e-twenty | 1 |
| 224 | e90/r92 | 1 |
| 225 | eba5316-20 | 1 |
| 226 | ebbs | 1 |
| 227 | ecm/pet/ct | 1 |
| 228 | education.before | 1 |
| 229 | effectiveness-obtainable | 1 |
| 230 | egfr/her-2 | 1 |
| 231 | egfr/p16 | 1 |
| 232 | ehocardiography | 1 |
| 233 | eikonometry | 1 |
| 234 | electro-radiology | 1 |
| 235 | epidata3.1 | 1 |
| 236 | epilepsy.within | 1 |
| 237 | eps-scores | 1 |
| 238 | ergometrine/ergometrinine | 1 |
| 239 | evidence-for | 1 |
| 240 | evidence-that | 1 |
| 241 | exone | 1 |
| 242 | expein | 1 |
| 243 | falgun | 1 |
| 244 | fh-negative | 1 |
| 245 | fields.considering | 1 |
| 246 | fine-balancing | 1 |
| 247 | follow-up-each | 1 |
| 248 | fos-related | 1 |
| 249 | ft-c. | 1 |
| 250 | furt | 1 |
| 251 | fviivwf | 1 |
| 252 | ghqs | 1 |
| 253 | glycated-h2a | 1 |
| 254 | goods-in | 1 |
| 255 | gsbsos | 1 |
| 256 | gsh/tga | 1 |
| 257 | haemolysis-associated | 1 |
| 258 | heat-illness/injury | 1 |
| 259 | heterophyidae | 1 |
| 260 | hexabenzylhexaazaisowurtzitane | 1 |
| 261 | hf.in | 1 |
| 262 | high-implanted | 1 |
| 263 | hiv/cm | 1 |
| 264 | honoré/joannes-boyau/gressens | 1 |
| 265 | hr-contained | 1 |
| 266 | hshrs | 1 |
| 267 | hydroneph-rosis | 1 |
| 268 | hysterotonics | 1 |
| 269 | ia-bon/a | 1 |
| 270 | icp-hf | 1 |
| 271 | ics.we | 1 |
| 272 | icu/hdus | 1 |
| 273 | ihc-p. | 1 |
| 274 | iief-improvement | 1 |
| 275 | ille-et-vilaine | 1 |
| 276 | immunobands | 1 |
| 277 | incubation.on | 1 |
| 278 | infering | 1 |
| 279 | inhibitory-kappab | 1 |
| 280 | inositols | 1 |
| 281 | instrumenting | 1 |
| 282 | intimas | 1 |
| 283 | ischaemia-reduces | 1 |
| 284 | ivfluids | 1 |
| 285 | iα-iβ | 1 |
| 286 | kakala | 1 |
| 287 | koa-ssi | 1 |
| 288 | kuvasai | 1 |
| 289 | laziness/competence | 1 |
| 290 | length/mo | 1 |
| 291 | life.both | 1 |
| 292 | life.from | 1 |
| 293 | life.objectives | 1 |
| 294 | ll/min | 1 |
| 295 | lofexedine | 1 |
| 296 | loss-of-consciousness | 1 |
| 297 | lyublyana | 1 |
| 298 | macroprolactinoma.note | 1 |
| 299 | maldi-ms. | 1 |
| 300 | maravirocand | 1 |
| 301 | maternité | 1 |
| 302 | mc'95 | 1 |
| 303 | mc/ | 1 |
| 304 | mda-ldl-ic | 1 |
| 305 | mepivacaine-tramadol | 1 |
| 306 | methoxyestrogens | 1 |
| 307 | mg2+-amp | 1 |
| 308 | mifepristone/prostaglandins | 1 |
| 309 | misestimating | 1 |
| 310 | misexpressing | 1 |
| 311 | mixed-episodes | 1 |
| 312 | mmp2/timp2 | 1 |
| 313 | mothers-neonates | 1 |
| 314 | motion-and | 1 |
| 315 | mozena | 1 |
| 316 | muc16/ca125 | 1 |
| 317 | mutationts | 1 |
| 318 | n-butil-2-cyanoacrylate | 1 |
| 319 | n-desmethylsildenafil | 1 |
| 320 | nac1 | 1 |
| 321 | nano-clinoptilolite | 1 |
| 322 | nebivolol-d4 | 1 |
| 323 | nebraska-lincoln | 1 |
| 324 | neoborn | 1 |
| 325 | neomales | 1 |
| 326 | no-reassuring | 1 |
| 327 | nodulin | 1 |
| 328 | non-ace-i/non-aiia | 1 |
| 329 | nurtrition | 1 |
| 330 | ocdd/f | 1 |
| 331 | oceanobacillus | 1 |
| 332 | oesophagus/stomach | 1 |
| 333 | one-regimen | 1 |
| 334 | organisms-and | 1 |
| 335 | osa-modification | 1 |
| 336 | over-emphasizing | 1 |
| 337 | oxaliplatin.as | 1 |
| 338 | pair-matching | 1 |
| 339 | paper/internet | 1 |
| 340 | paroxonase-1 | 1 |
| 341 | participants.comparing | 1 |
| 342 | participants.on | 1 |
| 343 | participantss | 1 |
| 344 | patf-3 | 1 |
| 345 | pc1-3 | 1 |
| 346 | pca-both | 1 |
| 347 | pcl-nanoparticles | 1 |
| 348 | pde1-4 | 1 |
| 349 | pharmacomodulation | 1 |
| 350 | physiotherapy.• | 1 |
| 351 | pick-ups | 1 |
| 352 | placentapercreta | 1 |
| 353 | pln10 | 1 |
| 354 | pma-treated | 1 |
| 355 | postopration | 1 |
| 356 | poststandard | 1 |
| 357 | pound23,807-below | 1 |
| 358 | practice.obstetricians | 1 |
| 359 | prague-motol | 1 |
| 360 | prestanding | 1 |
| 361 | psychoanaleptics | 1 |
| 362 | psychologist-administered | 1 |
| 363 | psychotropic-combination | 1 |
| 364 | purchase/non-purchase | 1 |
| 365 | pyridyltriazine | 1 |
| 366 | pyrimidinylnitrenes | 1 |
| 367 | q1-q4 | 1 |
| 368 | qcg001 | 1 |
| 369 | quadripolar-crt | 1 |
| 370 | r-o-demethyl-ven | 1 |
| 371 | r-ondansetron | 1 |
| 372 | r93 | 1 |
| 373 | re-infarction/death | 1 |
| 374 | re-interpreting | 1 |
| 375 | reasons.of | 1 |
| 376 | receiving/providing | 1 |
| 377 | regions-including | 1 |
| 378 | regulating/attenuating | 1 |
| 379 | reifying | 1 |
| 380 | rhabdomyolysis.of | 1 |
| 381 | risk-scores | 1 |
| 382 | rmbss | 1 |
| 383 | rom/sdm | 1 |
| 384 | rs10520097 | 1 |
| 385 | rs12757998 | 1 |
| 386 | rs3124740 | 1 |
| 387 | rs6350-rs463379 | 1 |
| 388 | rswas | 1 |
| 389 | rt+as | 1 |
| 390 | rybgp | 1 |
| 391 | s-ipth | 1 |
| 392 | sabin-2 | 1 |
| 393 | saliva.although | 1 |
| 394 | salzburg-province | 1 |
| 395 | sam-ples | 1 |
| 396 | sand.all | 1 |
| 397 | scfrs | 1 |
| 398 | scirpusyagara | 1 |
| 399 | screen-negatives | 1 |
| 400 | sild-poloxamer | 1 |
| 401 | sims-rct | 1 |
| 402 | siv-infection | 1 |
| 403 | skewering | 1 |
| 404 | snp2 | 1 |
| 405 | society-that | 1 |
| 406 | sodis-users | 1 |
| 407 | sodium-currents | 1 |
| 408 | speakerspecific | 1 |
| 409 | spectroscopy-both | 1 |
| 410 | stanching | 1 |
| 411 | steroid-responders | 1 |
| 412 | stigmaeus | 1 |
| 413 | supercenters | 1 |
| 414 | syphilitics | 1 |
| 415 | tac-males | 1 |
| 416 | temperature-morbidity-relationship | 1 |
| 417 | testosterone.1 | 1 |
| 418 | tga-vsd | 1 |
| 419 | tgf-βin | 1 |
| 420 | the.sensor | 1 |
| 421 | thermo-trps | 1 |
| 422 | thiazolopyrimidines | 1 |
| 423 | thixotropy | 1 |
| 424 | tiaomian | 1 |
| 425 | title-analysis | 1 |
| 426 | tl-i-iii | 1 |
| 427 | tocolyse | 1 |
| 428 | tolerance/tachyphylaxis | 1 |
| 429 | tolerestat | 1 |
| 430 | tongbu | 1 |
| 431 | toxin-assisted | 1 |
| 432 | tp-e. | 1 |
| 433 | trans-2-methyl-3-hydroxy-tetrahydrofuran | 1 |
| 434 | triacylglycerol/hdl | 1 |
| 435 | tricking | 1 |
| 436 | ts-mutations | 1 |
| 437 | tsbye-g. | 1 |
| 438 | tt-ctc | 1 |
| 439 | tuk2 | 1 |
| 440 | uighurs | 1 |
| 441 | under-staffing | 1 |
| 442 | underadherence | 1 |
| 443 | underestimators | 1 |
| 444 | uneradicated | 1 |
| 445 | use/initiation | 1 |
| 446 | valganciclovirin | 1 |
| 447 | walking/week | 1 |
| 448 | water-on | 1 |
| 449 | wedlock | 1 |
| 450 | whom16 | 1 |
| 451 | whomever | 1 |
| 452 | wmsis | 1 |
| 453 | women.for | 1 |
| 454 | xenium | 1 |
| 455 | ¹³c-cellulose | 1 |
| 456 | α-crocetin | 1 |
| 457 | α6-integrin | 1 |
| 458 | β1-adrenoreceptors | 1 |
| 459 | ‘blended | 1 |
| 460 | €20,000/qaly | 1 |
| 461 | ≤15° | 1 |
| 462 | ≥12.8 | 1 |
| 463 | ≥12months | 1 |
| 464 | ≥16° | 1 |
| 465 | ≥270 | 1 |
| 466 | ≥90º | 1 |
| 467 | ⩽0.01 | 1 |
| 1 | 'jumping | 1 |
| 2 | 'marrying | 1 |
| 3 | 'redesigning | 1 |
| 4 | -20mpa | 1 |
| 5 | 0.018-0.032mg/kg | 1 |
| 6 | 0.1349 | 1 |
| 7 | 01.01-31.12.2001 | 1 |
| 8 | 1,090,640 | 1 |
| 9 | 1,4-diaryl-1,2,3-triazoles | 1 |
| 10 | 1,7-seco-2,7'-cyclolignane | 1 |
| 11 | 1-3+ | 1 |
| 12 | 1.3g/l/h | 1 |
| 13 | 1.8min | 1 |
| 14 | 10.6°/cm | 1 |
| 15 | 10/1980-12/1985 | 1 |
| 16 | 100-1000k | 2 |
| 17 | 10cm² | 1 |
| 18 | 110,718 | 1 |
| 19 | 12,450 | 1 |
| 20 | 120-200mg/dl | 1 |
| 21 | 130-165°f | 1 |
| 22 | 14-membered-ring | 1 |
| 23 | 15-25°c | 1 |
| 24 | 15-30/h | 1 |
| 25 | 15mg/day | 1 |
| 26 | 18,510 | 1 |
| 27 | 18,571 | 1 |
| 28 | 1928-1953 | 1 |
| 29 | 1954-2003 | 1 |
| 30 | 1979-82 | 2 |
| 31 | 1982-1985 | 1 |
| 32 | 1985-1997 | 2 |
| 33 | 1h-pyrrolizine | 1 |
| 34 | 2,3,4,9-tetrahydro-1h-carbazol-1-one | 1 |
| 35 | 2,5-diphenyl-1,3,4-oxadiazoles | 1 |
| 36 | 2-amino-2-deoxy-d-glucose | 1 |
| 37 | 2-amino-2-methyl-1,3-propanediol | 1 |
| 38 | 2.92° | 1 |
| 39 | 20,400 | 1 |
| 40 | 2003-surpassing | 1 |
| 41 | 20cigarettes/day | 1 |
| 42 | 21,457 | 2 |
| 43 | 222,148 | 1 |
| 44 | 23.4-27.5 | 1 |
| 45 | 2374/53 | 1 |
| 46 | 24,075 | 1 |
| 47 | 28,107 | 1 |
| 48 | 3,17-dicarboxamides | 1 |
| 49 | 3,3'-dimethoxy-7,7'-epoxylignane-4,4'-diol | 1 |
| 50 | 3,903 | 1 |
| 51 | 3-aryl-3-arylmethoxy-azetidines | 1 |
| 52 | 3-arylideneflavanones | 1 |
| 53 | 300. | 1 |
| 54 | 300±30μm | 1 |
| 55 | 35,869 | 2 |
| 56 | 36755 | 1 |
| 57 | 372bp | 1 |
| 58 | 3873 | 2 |
| 59 | 3h-l-glucose | 1 |
| 60 | 4'-methylbiphenyl-2-carbonitrile | 1 |
| 61 | 4-aryl-3-methyl-4-piperidinemethanols | 1 |
| 62 | 4.1±1.4mm | 1 |
| 63 | 4.3±0.1 | 1 |
| 64 | 4/107 | 1 |
| 65 | 40-80mg/day | 1 |
| 66 | 40degrees | 1 |
| 67 | 4402 | 1 |
| 68 | 5,945 | 1 |
| 69 | 5-substituted-2-amino-1,3,4-thiadiazoles | 1 |
| 70 | 5-substituted-3,4-diphenylfuran-2-ones | 1 |
| 71 | 519/14 | 1 |
| 72 | 5498 | 4 |
| 73 | 5504 | 1 |
| 74 | 59,800 | 1 |
| 75 | 6,586 | 1 |
| 76 | 6.1+/-5.6 | 1 |
| 77 | 6.4-4.5 | 1 |
| 78 | 61° | 1 |
| 79 | 6366 | 1 |
| 80 | 64,236 | 1 |
| 81 | 68,230 | 1 |
| 82 | 6m2c | 1 |
| 83 | 70±10years | 1 |
| 84 | 75045 | 1 |
| 85 | 8191 | 1 |
| 86 | 81of | 1 |
| 87 | 83.7years | 1 |
| 88 | 8862 | 1 |
| 89 | 90°on | 1 |
| 90 | 9114 | 1 |
| 91 | 9819 | 1 |
| 92 | 99mtc-diphosphonates | 1 |
| 93 | abuse/use | 1 |
| 94 | action-targeting | 1 |
| 95 | activation-timing | 1 |
| 96 | ad-though | 1 |
| 97 | ad.1,2 | 1 |
| 98 | adhd/hkd | 1 |
| 99 | adhesive-tape | 1 |
| 100 | adhesive/cement | 1 |
| 101 | adipositas++ | 1 |
| 102 | affixing | 1 |
| 103 | africa׳s | 1 |
| 104 | agropyron | 1 |
| 105 | aiden.what | 1 |
| 106 | ais/tia | 1 |
| 107 | alkalinising | 1 |
| 108 | all-cis-1,2,4,5- | 1 |
| 109 | allele*3 | 1 |
| 110 | alpha2m | 1 |
| 111 | aminomutases | 1 |
| 112 | amir-al-momenin | 2 |
| 113 | anal-gesia | 1 |
| 114 | analysis.there | 4 |
| 115 | ancylostomids | 1 |
| 116 | android-based | 1 |
| 117 | anti-1,2-disubstituted-3,4-pentadien-1-amines | 1 |
| 118 | anti-infective-treated | 5 |
| 119 | antimicrobics | 1 |
| 120 | antzg1 | 1 |
| 121 | any-duration | 1 |
| 122 | aortosclerosis | 1 |
| 123 | arba | 5 |
| 124 | aroclors | 1 |
| 125 | articles.we | 2 |
| 126 | asia-for | 1 |
| 127 | atorvastatin/simvastatin | 1 |
| 128 | awareness-before | 1 |
| 129 | bacteriophagetherapy | 1 |
| 130 | bal-cells | 1 |
| 131 | bayankhongor | 1 |
| 132 | beamlets | 1 |
| 133 | benzofuroindolines | 1 |
| 134 | betaine/l | 1 |
| 135 | bias'assessment | 1 |
| 136 | bias.amongst | 1 |
| 137 | bias.for | 5 |
| 138 | bias.in | 1 |
| 139 | bias.only | 1 |
| 140 | bicuspidizing | 1 |
| 141 | biodoor | 1 |
| 142 | biosubstrates | 1 |
| 143 | blinding.in | 1 |
| 144 | bmp2+tgfβ1 | 1 |
| 145 | bp-3was | 1 |
| 146 | butaconazole | 1 |
| 147 | c1+2 | 1 |
| 148 | ca-725 | 1 |
| 149 | calf-raises | 1 |
| 150 | callovo-oxfordian | 1 |
| 151 | cams-how | 1 |
| 152 | canales | 4 |
| 153 | cases.at | 1 |
| 154 | cbt/ex | 1 |
| 155 | cctvs | 1 |
| 156 | cdc-treatment | 1 |
| 157 | cddp-5fu | 1 |
| 158 | cddp.at | 1 |
| 159 | cementing.in | 1 |
| 160 | centreing | 1 |
| 161 | cgog | 1 |
| 162 | child-sizing | 1 |
| 163 | children.overall | 1 |
| 164 | chldren | 1 |
| 165 | choleretics | 1 |
| 166 | col4a3/β-actin | 1 |
| 167 | control.citalopram | 1 |
| 168 | controls-a | 1 |
| 169 | coprinus | 4 |
| 170 | cross-trimester | 1 |
| 171 | crt-d/icd | 1 |
| 172 | ct3n0-1m0 | 1 |
| 173 | customising | 2 |
| 174 | cyanide-bound | 1 |
| 175 | cygb-mediated | 2 |
| 176 | d/adc | 1 |
| 177 | dabrowa | 2 |
| 178 | dairycomp | 1 |
| 179 | diabetes-hypertension-hypercholesterolemia | 1 |
| 180 | dicontinuating | 1 |
| 181 | disadvantaging | 1 |
| 182 | discolouring | 1 |
| 183 | discontination | 1 |
| 184 | discontinuation/switching | 1 |
| 185 | discussion.in | 1 |
| 186 | diseases-version | 1 |
| 187 | domperidone/kg | 2 |
| 188 | dsm-iv-ad | 1 |
| 189 | e-twenty | 1 |
| 190 | e90/r92 | 1 |
| 191 | eba5316-20 | 1 |
| 192 | ebbs | 1 |
| 193 | ecm/pet/ct | 1 |
| 194 | education.before | 1 |
| 195 | effectiveness-obtainable | 1 |
| 196 | egfr/her-2 | 1 |
| 197 | egfr/p16 | 1 |
| 198 | ehocardiography | 1 |
| 199 | eikonometry | 1 |
| 200 | electro-radiology | 1 |
| 201 | enucleating | 3 |
| 202 | epidata3.1 | 1 |
| 203 | epilepsy.within | 1 |
| 204 | eps-scores | 1 |
| 205 | ergometrine/ergometrinine | 1 |
| 206 | evidence-for | 1 |
| 207 | evidence-that | 1 |
| 208 | evidence.whereas | 2 |
| 209 | exone | 1 |
| 210 | expein | 1 |
| 211 | falgun | 1 |
| 212 | fh-negative | 1 |
| 213 | fields.considering | 1 |
| 214 | fine-balancing | 1 |
| 215 | flp-in | 2 |
| 216 | follow-up-each | 1 |
| 217 | fos-related | 1 |
| 218 | ft-c. | 1 |
| 219 | ft4-levels | 2 |
| 220 | furt | 1 |
| 221 | fviivwf | 1 |
| 222 | gd-2 | 4 |
| 223 | ghqs | 1 |
| 224 | gidan | 2 |
| 225 | glucose/sucrose | 4 |
| 226 | glycated-h2a | 1 |
| 227 | goods-in | 1 |
| 228 | gsbsos | 1 |
| 229 | gsh/tga | 1 |
| 230 | haemolysis-associated | 1 |
| 231 | heat-illness/injury | 1 |
| 232 | hepa-1 | 3 |
| 233 | heterophyidae | 1 |
| 234 | hexabenzylhexaazaisowurtzitane | 1 |
| 235 | hf.in | 1 |
| 236 | high-implanted | 1 |
| 237 | hiv/cm | 1 |
| 238 | honoré/joannes-boyau/gressens | 1 |
| 239 | hr-contained | 1 |
| 240 | hshrs | 1 |
| 241 | hydroneph-rosis | 1 |
| 242 | hydroscopicity | 2 |
| 243 | hysterotonics | 1 |
| 244 | ia-bon/a | 1 |
| 245 | icp-hf | 1 |
| 246 | icrf | 2 |
| 247 | ics.we | 1 |
| 248 | ict-ccrt | 2 |
| 249 | icu/hdus | 1 |
| 250 | ihc-p. | 1 |
| 251 | iief-improvement | 1 |
| 252 | ille-et-vilaine | 1 |
| 253 | immunobands | 1 |
| 254 | incubation.on | 1 |
| 255 | infering | 1 |
| 256 | inhibitory-kappab | 1 |
| 257 | inositols | 1 |
| 258 | instrumenting | 1 |
| 259 | intimas | 1 |
| 260 | ischaemia-reduces | 1 |
| 261 | ivfluids | 1 |
| 262 | iα-iβ | 1 |
| 263 | jbir-108 | 2 |
| 264 | kakala | 1 |
| 265 | koa-ssi | 1 |
| 266 | kuvasai | 1 |
| 267 | laziness/competence | 1 |
| 268 | legitimizing | 3 |
| 269 | length/mo | 1 |
| 270 | life.both | 1 |
| 271 | life.from | 1 |
| 272 | life.objectives | 1 |
| 273 | ll/min | 1 |
| 274 | lofexedine | 1 |
| 275 | loss-of-consciousness | 1 |
| 276 | lyublyana | 1 |
| 277 | macroprolactinoma.note | 1 |
| 278 | maldi-ms. | 1 |
| 279 | maravirocand | 1 |
| 280 | maternité | 1 |
| 281 | mc'95 | 1 |
| 282 | mc/ | 1 |
| 283 | mda-ldl-ic | 1 |
| 284 | mepivacaine-tramadol | 1 |
| 285 | methoxyestrogens | 1 |
| 286 | mg2+-amp | 1 |
| 287 | mifepristone/prostaglandins | 1 |
| 288 | misestimating | 1 |
| 289 | misexpressing | 1 |
| 290 | mixed-episodes | 1 |
| 291 | mmp2/timp2 | 1 |
| 292 | mothers-neonates | 1 |
| 293 | motion-and | 1 |
| 294 | mozena | 1 |
| 295 | muc16/ca125 | 1 |
| 296 | mutationts | 1 |
| 297 | n-butil-2-cyanoacrylate | 1 |
| 298 | n-desmethylsildenafil | 1 |
| 299 | nac1 | 1 |
| 300 | nano-clinoptilolite | 1 |
| 301 | nebivolol-d4 | 1 |
| 302 | nebraska-lincoln | 1 |
| 303 | neoborn | 1 |
| 304 | neomales | 1 |
| 305 | newborns/infants | 2 |
| 306 | no-reassuring | 1 |
| 307 | nodulin | 1 |
| 308 | non-ace-i/non-aiia | 1 |
| 309 | npp/kg | 3 |
| 310 | nurtrition | 1 |
| 311 | ocdd/f | 1 |
| 312 | oceanobacillus | 1 |
| 313 | oesophagus/stomach | 1 |
| 314 | one-regimen | 1 |
| 315 | organisms-and | 1 |
| 316 | osa-modification | 1 |
| 317 | over-emphasizing | 1 |
| 318 | oxaliplatin.as | 1 |
| 319 | pair-matching | 1 |
| 320 | paper/internet | 1 |
| 321 | paroxonase-1 | 1 |
| 322 | parthenoclone | 2 |
| 323 | participants.comparing | 1 |
| 324 | participants.on | 1 |
| 325 | participantss | 1 |
| 326 | patf-3 | 1 |
| 327 | pc1-3 | 1 |
| 328 | pca-both | 1 |
| 329 | pcc+pce | 4 |
| 330 | pcl-nanoparticles | 1 |
| 331 | pde1-4 | 1 |
| 332 | perdeuterated | 2 |
| 333 | pharmacomodulation | 1 |
| 334 | physiotherapy.• | 1 |
| 335 | pick-ups | 1 |
| 336 | placentapercreta | 1 |
| 337 | pln10 | 1 |
| 338 | pma-treated | 1 |
| 339 | postbunionectomy | 2 |
| 340 | postopration | 1 |
| 341 | poststandard | 1 |
| 342 | pound23,807-below | 1 |
| 343 | practice.obstetricians | 1 |
| 344 | prague-motol | 1 |
| 345 | pre-abortion | 2 |
| 346 | pre-maturely | 2 |
| 347 | prestanding | 1 |
| 348 | previously-studied | 2 |
| 349 | psychoanaleptics | 1 |
| 350 | psychologist-administered | 1 |
| 351 | psychotropic-combination | 1 |
| 352 | purchase/non-purchase | 1 |
| 353 | pyridyltriazine | 1 |
| 354 | pyrimidinylnitrenes | 1 |
| 355 | q1-q4 | 1 |
| 356 | qcg001 | 1 |
| 357 | qizhi | 7 |
| 358 | quadripolar-crt | 1 |
| 359 | r-o-demethyl-ven | 1 |
| 360 | r-ondansetron | 1 |
| 361 | r93 | 1 |
| 362 | re-infarction/death | 1 |
| 363 | re-interpreting | 1 |
| 364 | reasons.of | 1 |
| 365 | receiving/providing | 1 |
| 366 | regions-including | 1 |
| 367 | regulating/attenuating | 1 |
| 368 | reifying | 1 |
| 369 | review- | 6 |
| 370 | rhabdomyolysis.of | 1 |
| 371 | risk-scores | 1 |
| 372 | rmbss | 1 |
| 373 | rom/sdm | 1 |
| 374 | rs10520097 | 1 |
| 375 | rs12757998 | 1 |
| 376 | rs3124740 | 1 |
| 377 | rs6350-rs463379 | 1 |
| 378 | rswas | 1 |
| 379 | rt+as | 1 |
| 380 | rybgp | 1 |
| 381 | s-ipth | 1 |
| 382 | sabal | 4 |
| 383 | sabin-2 | 1 |
| 384 | saliva.although | 1 |
| 385 | salzburg-province | 1 |
| 386 | sam-ples | 1 |
| 387 | sand.all | 1 |
| 388 | scfrs | 1 |
| 389 | scirpusyagara | 1 |
| 390 | screen-negatives | 1 |
| 391 | sild-poloxamer | 1 |
| 392 | sims-rct | 1 |
| 393 | siv-infection | 1 |
| 394 | skewering | 1 |
| 395 | snp2 | 1 |
| 396 | society-that | 1 |
| 397 | sodis-users | 1 |
| 398 | sodium-currents | 1 |
| 399 | speakerspecific | 1 |
| 400 | spectroscopy-both | 1 |
| 401 | stanching | 1 |
| 402 | steroid-responders | 1 |
| 403 | stigmaeus | 1 |
| 404 | supercenters | 1 |
| 405 | syphilitics | 1 |
| 406 | tac-males | 1 |
| 407 | temperature-morbidity-relationship | 1 |
| 408 | testosterone.1 | 1 |
| 409 | tga-vsd | 1 |
| 410 | tgf-βin | 1 |
| 411 | the.sensor | 1 |
| 412 | thermo-trps | 1 |
| 413 | thiazolopyrimidines | 1 |
| 414 | thixotropy | 1 |
| 415 | tiaomian | 1 |
| 416 | title-analysis | 1 |
| 417 | tl-i-iii | 1 |
| 418 | tocolyse | 1 |
| 419 | tolerance/tachyphylaxis | 1 |
| 420 | tolerestat | 1 |
| 421 | tongbu | 1 |
| 422 | top-dose | 2 |
| 423 | toxin-assisted | 1 |
| 424 | tp-e. | 1 |
| 425 | trans-2-methyl-3-hydroxy-tetrahydrofuran | 1 |
| 426 | triacylglycerol/hdl | 1 |
| 427 | tricking | 1 |
| 428 | ts-mutations | 1 |
| 429 | tsbye-g. | 1 |
| 430 | tt-ctc | 1 |
| 431 | tuk2 | 1 |
| 432 | uighurs | 1 |
| 433 | under-staffing | 1 |
| 434 | underadherence | 1 |
| 435 | underestimators | 1 |
| 436 | uneradicated | 1 |
| 437 | use/initiation | 1 |
| 438 | valganciclovirin | 1 |
| 439 | vhr | 4 |
| 440 | viewing- | 2 |
| 441 | walking/week | 1 |
| 442 | water-on | 1 |
| 443 | wedlock | 1 |
| 444 | whom | 7,851 |
| 445 | whom16 | 1 |
| 446 | whomever | 1 |
| 447 | wmsis | 1 |
| 448 | women.for | 1 |
| 449 | wwox-related | 2 |
| 450 | xenium | 1 |
| 451 | yangchangwan | 2 |
| 452 | ~1000 | 3 |
| 453 | ¹³c-cellulose | 1 |
| 454 | świetokrzyskie | 2 |
| 455 | α-crocetin | 1 |
| 456 | α6-integrin | 1 |
| 457 | β1-adrenoreceptors | 1 |
| 458 | ‘blended | 1 |
| 459 | €20,000/qaly | 1 |
| 460 | €50 | 2 |
| 461 | ≤15° | 1 |
| 462 | ≥12.8 | 1 |
| 463 | ≥12months | 1 |
| 464 | ≥16° | 1 |
| 465 | ≥270 | 1 |
| 466 | ≥90º | 1 |
| 467 | ⩽0.01 | 1 |
| 1 | adipositas++ | 1 |
| 2 | 1-3+ | 1 |
| 3 | all-cis-1,2,4,5- | 1 |
| 4 | viewing- | 2 |
| 5 | review- | 6 |
| 6 | 300. | 1 |
| 7 | ft-c. | 1 |
| 8 | tp-e. | 1 |
| 9 | tsbye-g. | 1 |
| 10 | ihc-p. | 1 |
| 11 | maldi-ms. | 1 |
| 12 | mc/ | 1 |
| 13 | ~1000 | 3 |
| 14 | 20,400 | 1 |
| 15 | 59,800 | 1 |
| 16 | 18,510 | 1 |
| 17 | pln10 | 1 |
| 18 | eba5316-20 | 1 |
| 19 | 68,230 | 1 |
| 20 | 1,090,640 | 1 |
| 21 | rs3124740 | 1 |
| 22 | 12,450 | 1 |
| 23 | €50 | 2 |
| 24 | ≥270 | 1 |
| 25 | ct3n0-1m0 | 1 |
| 26 | hepa-1 | 3 |
| 27 | paroxonase-1 | 1 |
| 28 | 4.3±0.1 | 1 |
| 29 | epidata3.1 | 1 |
| 30 | testosterone.1 | 1 |
| 31 | ⩽0.01 | 1 |
| 32 | 01.01-31.12.2001 | 1 |
| 33 | qcg001 | 1 |
| 34 | 18,571 | 1 |
| 35 | 8191 | 1 |
| 36 | nac1 | 1 |
| 37 | antzg1 | 1 |
| 38 | bmp2+tgfβ1 | 1 |
| 39 | c1+2 | 1 |
| 40 | ad.1,2 | 1 |
| 41 | gd-2 | 4 |
| 42 | sabin-2 | 1 |
| 43 | egfr/her-2 | 1 |
| 44 | 4402 | 1 |
| 45 | 8862 | 1 |
| 46 | 1979-82 | 2 |
| 47 | e90/r92 | 1 |
| 48 | tuk2 | 1 |
| 49 | mmp2/timp2 | 1 |
| 50 | snp2 | 1 |
| 51 | allele*3 | 1 |
| 52 | pc1-3 | 1 |
| 53 | patf-3 | 1 |
| 54 | 1954-2003 | 1 |
| 55 | 3,903 | 1 |
| 56 | 2374/53 | 1 |
| 57 | 1928-1953 | 1 |
| 58 | 3873 | 2 |
| 59 | r93 | 1 |
| 60 | pde1-4 | 1 |
| 61 | 5504 | 1 |
| 62 | 519/14 | 1 |
| 63 | 9114 | 1 |
| 64 | nebivolol-d4 | 1 |
| 65 | q1-q4 | 1 |
| 66 | 6.4-4.5 | 1 |
| 67 | 23.4-27.5 | 1 |
| 68 | muc16/ca125 | 1 |
| 69 | ca-725 | 1 |
| 70 | 75045 | 1 |
| 71 | 5,945 | 1 |
| 72 | 36755 | 1 |
| 73 | 24,075 | 1 |
| 74 | 1982-1985 | 1 |
| 75 | 10/1980-12/1985 | 1 |
| 76 | mc'95 | 1 |
| 77 | 6.1+/-5.6 | 1 |
| 78 | whom16 | 1 |
| 79 | egfr/p16 | 1 |
| 80 | 64,236 | 1 |
| 81 | 6366 | 1 |
| 82 | 6,586 | 1 |
| 83 | 28,107 | 1 |
| 84 | 4/107 | 1 |
| 85 | 21,457 | 2 |
| 86 | rs10520097 | 1 |
| 87 | 1985-1997 | 2 |
| 88 | ≥12.8 | 1 |
| 89 | jbir-108 | 2 |
| 90 | 110,718 | 1 |
| 91 | 222,148 | 1 |
| 92 | 5498 | 4 |
| 93 | rs12757998 | 1 |
| 94 | 9819 | 1 |
| 95 | 0.1349 | 1 |
| 96 | 35,869 | 2 |
| 97 | rs6350-rs463379 | 1 |
| 98 | controls-a | 1 |
| 99 | ia-bon/a | 1 |
| 100 | glycated-h2a | 1 |
| 101 | arba | 5 |
| 102 | gsh/tga | 1 |
| 103 | non-ace-i/non-aiia | 1 |
| 104 | diabetes-hypertension-hypercholesterolemia | 1 |
| 105 | anal-gesia | 1 |
| 106 | ais/tia | 1 |
| 107 | kakala | 1 |
| 108 | lyublyana | 1 |
| 109 | mozena | 1 |
| 110 | -20mpa | 1 |
| 111 | scirpusyagara | 1 |
| 112 | placentapercreta | 1 |
| 113 | dabrowa | 2 |
| 114 | inhibitory-kappab | 1 |
| 115 | 6m2c | 1 |
| 116 | d/adc | 1 |
| 117 | mda-ldl-ic | 1 |
| 118 | speakerspecific | 1 |
| 119 | tt-ctc | 1 |
| 120 | 15-25°c | 1 |
| 121 | dsm-iv-ad | 1 |
| 122 | crt-d/icd | 1 |
| 123 | ‘blended | 1 |
| 124 | previously-studied | 2 |
| 125 | hr-contained | 1 |
| 126 | psychologist-administered | 1 |
| 127 | android-based | 1 |
| 128 | uneradicated | 1 |
| 129 | pma-treated | 1 |
| 130 | anti-infective-treated | 5 |
| 131 | haemolysis-associated | 1 |
| 132 | cygb-mediated | 2 |
| 133 | fos-related | 1 |
| 134 | wwox-related | 2 |
| 135 | perdeuterated | 2 |
| 136 | high-implanted | 1 |
| 137 | toxin-assisted | 1 |
| 138 | adhd/hkd | 1 |
| 139 | motion-and | 1 |
| 140 | organisms-and | 1 |
| 141 | maravirocand | 1 |
| 142 | cyanide-bound | 1 |
| 143 | poststandard | 1 |
| 144 | tga-vsd | 1 |
| 145 | heterophyidae | 1 |
| 146 | underadherence | 1 |
| 147 | laziness/competence | 1 |
| 148 | salzburg-province | 1 |
| 149 | pcc+pce | 4 |
| 150 | świetokrzyskie | 2 |
| 151 | effectiveness-obtainable | 1 |
| 152 | 4'-methylbiphenyl-2-carbonitrile | 1 |
| 153 | butaconazole | 1 |
| 154 | 1,7-seco-2,7'-cyclolignane | 1 |
| 155 | hexabenzylhexaazaisowurtzitane | 1 |
| 156 | ille-et-vilaine | 1 |
| 157 | lofexedine | 1 |
| 158 | ergometrine/ergometrinine | 1 |
| 159 | pyridyltriazine | 1 |
| 160 | 1h-pyrrolizine | 1 |
| 161 | 2,3,4,9-tetrahydro-1h-carbazol-1-one | 1 |
| 162 | parthenoclone | 2 |
| 163 | exone | 1 |
| 164 | adhesive-tape | 1 |
| 165 | analysis.there | 4 |
| 166 | awareness-before | 1 |
| 167 | education.before | 1 |
| 168 | purchase/non-purchase | 1 |
| 169 | 2-amino-2-deoxy-d-glucose | 1 |
| 170 | 3h-l-glucose | 1 |
| 171 | top-dose | 2 |
| 172 | ¹³c-cellulose | 1 |
| 173 | glucose/sucrose | 4 |
| 174 | abuse/use | 1 |
| 175 | tocolyse | 1 |
| 176 | n-butil-2-cyanoacrylate | 1 |
| 177 | nano-clinoptilolite | 1 |
| 178 | macroprolactinoma.note | 1 |
| 179 | fh-negative | 1 |
| 180 | ics.we | 1 |
| 181 | articles.we | 2 |
| 182 | ocdd/f | 1 |
| 183 | icp-hf | 1 |
| 184 | rhabdomyolysis.of | 1 |
| 185 | reasons.of | 1 |
| 186 | 81of | 1 |
| 187 | icrf | 2 |
| 188 | fviivwf | 1 |
| 189 | 130-165°f | 1 |
| 190 | domperidone/kg | 2 |
| 191 | 0.018-0.032mg/kg | 1 |
| 192 | npp/kg | 3 |
| 193 | fine-balancing | 1 |
| 194 | receiving/providing | 1 |
| 195 | prestanding | 1 |
| 196 | regions-including | 1 |
| 197 | centreing | 1 |
| 198 | under-staffing | 1 |
| 199 | disadvantaging | 1 |
| 200 | stanching | 1 |
| 201 | pair-matching | 1 |
| 202 | discontinuation/switching | 1 |
| 203 | tricking | 1 |
| 204 | activation-timing | 1 |
| 205 | 'redesigning | 1 |
| 206 | 'jumping | 1 |
| 207 | 14-membered-ring | 1 |
| 208 | participants.comparing | 1 |
| 209 | fields.considering | 1 |
| 210 | infering | 1 |
| 211 | skewering | 1 |
| 212 | discolouring | 1 |
| 213 | no-reassuring | 1 |
| 214 | customising | 2 |
| 215 | alkalinising | 1 |
| 216 | 2003-surpassing | 1 |
| 217 | misexpressing | 1 |
| 218 | enucleating | 3 |
| 219 | misestimating | 1 |
| 220 | regulating/attenuating | 1 |
| 221 | dicontinuating | 1 |
| 222 | action-targeting | 1 |
| 223 | re-interpreting | 1 |
| 224 | instrumenting | 1 |
| 225 | affixing | 1 |
| 226 | reifying | 1 |
| 227 | 'marrying | 1 |
| 228 | bicuspidizing | 1 |
| 229 | legitimizing | 3 |
| 230 | child-sizing | 1 |
| 231 | over-emphasizing | 1 |
| 232 | cgog | 1 |
| 233 | 15-30/h | 1 |
| 234 | 1.3g/l/h | 1 |
| 235 | follow-up-each | 1 |
| 236 | oesophagus/stomach | 1 |
| 237 | ad-though | 1 |
| 238 | saliva.although | 1 |
| 239 | re-infarction/death | 1 |
| 240 | pca-both | 1 |
| 241 | spectroscopy-both | 1 |
| 242 | life.both | 1 |
| 243 | s-ipth | 1 |
| 244 | kuvasai | 1 |
| 245 | qizhi | 7 |
| 246 | tl-i-iii | 1 |
| 247 | koa-ssi | 1 |
| 248 | 100-1000k | 2 |
| 249 | wedlock | 1 |
| 250 | walking/week | 1 |
| 251 | betaine/l | 1 |
| 252 | sabal | 4 |
| 253 | 120-200mg/dl | 1 |
| 254 | triacylglycerol/hdl | 1 |
| 255 | n-desmethylsildenafil | 1 |
| 256 | sand.all | 1 |
| 257 | children.overall | 1 |
| 258 | mepivacaine-tramadol | 1 |
| 259 | 3,3'-dimethoxy-7,7'-epoxylignane-4,4'-diol | 1 |
| 260 | 2-amino-2-methyl-1,3-propanediol | 1 |
| 261 | prague-motol | 1 |
| 262 | alpha2m | 1 |
| 263 | control.citalopram | 1 |
| 264 | hiv/cm | 1 |
| 265 | 10.6°/cm | 1 |
| 266 | rom/sdm | 1 |
| 267 | 4.1±1.4mm | 1 |
| 268 | whom | 7,851 |
| 269 | life.from | 1 |
| 270 | xenium | 1 |
| 271 | 300±30μm | 1 |
| 272 | gidan | 2 |
| 273 | callovo-oxfordian | 1 |
| 274 | tiaomian | 1 |
| 275 | trans-2-methyl-3-hydroxy-tetrahydrofuran | 1 |
| 276 | yangchangwan | 2 |
| 277 | one-regimen | 1 |
| 278 | chldren | 1 |
| 279 | r-o-demethyl-ven | 1 |
| 280 | flp-in | 2 |
| 281 | goods-in | 1 |
| 282 | hf.in | 1 |
| 283 | blinding.in | 1 |
| 284 | cementing.in | 1 |
| 285 | discussion.in | 1 |
| 286 | bias.in | 1 |
| 287 | expein | 1 |
| 288 | epilepsy.within | 1 |
| 289 | nodulin | 1 |
| 290 | ll/min | 1 |
| 291 | 1.8min | 1 |
| 292 | amir-al-momenin | 2 |
| 293 | α6-integrin | 1 |
| 294 | valganciclovirin | 1 |
| 295 | atorvastatin/simvastatin | 1 |
| 296 | col4a3/β-actin | 1 |
| 297 | α-crocetin | 1 |
| 298 | tgf-βin | 1 |
| 299 | nebraska-lincoln | 1 |
| 300 | water-on | 1 |
| 301 | incubation.on | 1 |
| 302 | participants.on | 1 |
| 303 | diseases-version | 1 |
| 304 | osa-modification | 1 |
| 305 | use/initiation | 1 |
| 306 | pharmacomodulation | 1 |
| 307 | psychotropic-combination | 1 |
| 308 | discontination | 1 |
| 309 | postopration | 1 |
| 310 | any-duration | 1 |
| 311 | siv-infection | 1 |
| 312 | nurtrition | 1 |
| 313 | pre-abortion | 2 |
| 314 | r-ondansetron | 1 |
| 315 | agropyron | 1 |
| 316 | 90°on | 1 |
| 317 | neoborn | 1 |
| 318 | falgun | 1 |
| 319 | length/mo | 1 |
| 320 | 372bp | 1 |
| 321 | rybgp | 1 |
| 322 | temperature-morbidity-relationship | 1 |
| 323 | mg2+-amp | 1 |
| 324 | dairycomp | 1 |
| 325 | sild-poloxamer | 1 |
| 326 | cross-trimester | 1 |
| 327 | whomever | 1 |
| 328 | vhr | 4 |
| 329 | asia-for | 1 |
| 330 | evidence-for | 1 |
| 331 | women.for | 1 |
| 332 | bias.for | 5 |
| 333 | bayankhongor | 1 |
| 334 | biodoor | 1 |
| 335 | the.sensor | 1 |
| 336 | rt+as | 1 |
| 337 | oxaliplatin.as | 1 |
| 338 | evidence.whereas | 2 |
| 339 | intimas | 1 |
| 340 | bp-3was | 1 |
| 341 | rswas | 1 |
| 342 | ebbs | 1 |
| 343 | antimicrobics | 1 |
| 344 | hysterotonics | 1 |
| 345 | choleretics | 1 |
| 346 | syphilitics | 1 |
| 347 | psychoanaleptics | 1 |
| 348 | ancylostomids | 1 |
| 349 | ivfluids | 1 |
| 350 | immunobands | 1 |
| 351 | ischaemia-reduces | 1 |
| 352 | 3,17-dicarboxamides | 1 |
| 353 | mixed-episodes | 1 |
| 354 | 40degrees | 1 |
| 355 | tac-males | 1 |
| 356 | neomales | 1 |
| 357 | canales | 4 |
| 358 | pcl-nanoparticles | 1 |
| 359 | 5-substituted-2-amino-1,3,4-thiadiazoles | 1 |
| 360 | 2,5-diphenyl-1,3,4-oxadiazoles | 1 |
| 361 | 1,4-diaryl-1,2,3-triazoles | 1 |
| 362 | sam-ples | 1 |
| 363 | pyrimidinylnitrenes | 1 |
| 364 | thiazolopyrimidines | 1 |
| 365 | 3-aryl-3-arylmethoxy-azetidines | 1 |
| 366 | benzofuroindolines | 1 |
| 367 | anti-1,2-disubstituted-3,4-pentadien-1-amines | 1 |
| 368 | 5-substituted-3,4-diphenylfuran-2-ones | 1 |
| 369 | 3-arylideneflavanones | 1 |
| 370 | risk-scores | 1 |
| 371 | eps-scores | 1 |
| 372 | aminomutases | 1 |
| 373 | calf-raises | 1 |
| 374 | mothers-neonates | 1 |
| 375 | 99mtc-diphosphonates | 1 |
| 376 | biosubstrates | 1 |
| 377 | screen-negatives | 1 |
| 378 | life.objectives | 1 |
| 379 | ≥12months | 1 |
| 380 | wmsis | 1 |
| 381 | hydroneph-rosis | 1 |
| 382 | aortosclerosis | 1 |
| 383 | title-analysis | 1 |
| 384 | tolerance/tachyphylaxis | 1 |
| 385 | ft4-levels | 2 |
| 386 | bal-cells | 1 |
| 387 | 4-aryl-3-methyl-4-piperidinemethanols | 1 |
| 388 | inositols | 1 |
| 389 | practice.obstetricians | 1 |
| 390 | methoxyestrogens | 1 |
| 391 | honoré/joannes-boyau/gressens | 1 |
| 392 | mifepristone/prostaglandins | 1 |
| 393 | ts-mutations | 1 |
| 394 | gsbsos | 1 |
| 395 | thermo-trps | 1 |
| 396 | pick-ups | 1 |
| 397 | ghqs | 1 |
| 398 | 70±10years | 1 |
| 399 | 83.7years | 1 |
| 400 | steroid-responders | 1 |
| 401 | sodis-users | 1 |
| 402 | supercenters | 1 |
| 403 | scfrs | 1 |
| 404 | hshrs | 1 |
| 405 | aroclors | 1 |
| 406 | underestimators | 1 |
| 407 | β1-adrenoreceptors | 1 |
| 408 | uighurs | 1 |
| 409 | rmbss | 1 |
| 410 | loss-of-consciousness | 1 |
| 411 | participantss | 1 |
| 412 | beamlets | 1 |
| 413 | newborns/infants | 2 |
| 414 | sodium-currents | 1 |
| 415 | mutationts | 1 |
| 416 | icu/hdus | 1 |
| 417 | stigmaeus | 1 |
| 418 | oceanobacillus | 1 |
| 419 | coprinus | 4 |
| 420 | cctvs | 1 |
| 421 | africa׳s | 1 |
| 422 | cddp.at | 1 |
| 423 | cases.at | 1 |
| 424 | evidence-that | 1 |
| 425 | society-that | 1 |
| 426 | aiden.what | 1 |
| 427 | tolerestat | 1 |
| 428 | ecm/pet/ct | 1 |
| 429 | sims-rct | 1 |
| 430 | paper/internet | 1 |
| 431 | adhesive/cement | 1 |
| 432 | iief-improvement | 1 |
| 433 | bias'assessment | 1 |
| 434 | cdc-treatment | 1 |
| 435 | quadripolar-crt | 1 |
| 436 | ict-ccrt | 2 |
| 437 | furt | 1 |
| 438 | bias.amongst | 1 |
| 439 | tongbu | 1 |
| 440 | cddp-5fu | 1 |
| 441 | cams-how | 1 |
| 442 | pound23,807-below | 1 |
| 443 | cbt/ex | 1 |
| 444 | 40-80mg/day | 1 |
| 445 | 15mg/day | 1 |
| 446 | 20cigarettes/day | 1 |
| 447 | electro-radiology | 1 |
| 448 | ehocardiography | 1 |
| 449 | €20,000/qaly | 1 |
| 450 | pre-maturely | 2 |
| 451 | bias.only | 1 |
| 452 | postbunionectomy | 2 |
| 453 | bacteriophagetherapy | 1 |
| 454 | thixotropy | 1 |
| 455 | eikonometry | 1 |
| 456 | heat-illness/injury | 1 |
| 457 | hydroscopicity | 2 |
| 458 | e-twenty | 1 |
| 459 | physiotherapy.• | 1 |
| 460 | maternité | 1 |
| 461 | 61° | 1 |
| 462 | 2.92° | 1 |
| 463 | ≤15° | 1 |
| 464 | ≥16° | 1 |
| 465 | 10cm² | 1 |
| 466 | iα-iβ | 1 |
| 467 | ≥90º | 1 |